Coya Therapeutics, Inc. (NASDAQ:COYA) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Coya Therapeutics, Inc. (NASDAQ:COYA) have received an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $16.00.

A number of brokerages have recently weighed in on COYA. Wall Street Zen lowered shares of Coya Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Coya Therapeutics in a report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Wednesday, January 21st. Chardan Capital reissued a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a research note on Monday, March 16th. Finally, D. Boral Capital restated a “buy” rating and set a $15.00 price target on shares of Coya Therapeutics in a research report on Monday, March 16th.

Institutional Investors Weigh In On Coya Therapeutics

Several institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. bought a new position in Coya Therapeutics during the 3rd quarter worth approximately $28,000. CIBC Private Wealth Group LLC bought a new stake in Coya Therapeutics in the fourth quarter valued at approximately $47,000. Occudo Quantitative Strategies LP purchased a new stake in shares of Coya Therapeutics during the fourth quarter valued at approximately $66,000. Lantern Wealth Advisors LLC purchased a new stake in shares of Coya Therapeutics during the third quarter valued at approximately $66,000. Finally, Oppenheimer & Co. Inc. bought a new position in shares of Coya Therapeutics in the fourth quarter worth approximately $81,000. 39.75% of the stock is currently owned by hedge funds and other institutional investors.

Coya Therapeutics Trading Up 0.2%

Shares of NASDAQ COYA opened at $4.22 on Tuesday. The stock has a market cap of $99.00 million, a price-to-earnings ratio of -3.32 and a beta of 0.23. Coya Therapeutics has a 1-year low of $3.94 and a 1-year high of $7.75. The stock’s 50-day moving average is $4.68 and its 200 day moving average is $5.50.

Coya Therapeutics (NASDAQ:COYA) last issued its earnings results on Monday, March 16th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.26). Coya Therapeutics had a negative return on equity of 62.76% and a negative net margin of 267.13%.The firm had revenue of $3.96 million during the quarter, compared to analysts’ expectations of $1.93 million. On average, analysts forecast that Coya Therapeutics will post -1.15 EPS for the current fiscal year.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.